



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2016

Treatment for patients with newly diagnosed glioblastoma–reply

Stupp, Roger ; Toms, Steven A ; Kesari, Santosh

DOI: <https://doi.org/10.1001/jama.2016.1847>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-130793>

Journal Article

Published Version

Originally published at:

Stupp, Roger; Toms, Steven A; Kesari, Santosh (2016). Treatment for patients with newly diagnosed glioblastoma–reply. JAMA : the Journal of the American Medical Association, 315(21):2348-2349.

DOI: <https://doi.org/10.1001/jama.2016.1847>

the cumulative risk for a suicide attempt or completion over the next year 10-fold and 100-fold, respectively.² Self-report is more sensitive for detecting suicidal ideation than clinician interviews.³ Depressed residents, evaluated by the HANDS inventory (Harvard Department of Psychiatry/National Depression Screening Day Scale), make 6.2 times as many medication errors per month.⁴ Underscoring the significance of depression data from surveys, clinical guidelines explicitly support their use in assessing and treating depression.⁵

In the article, we provided a table of the sensitivities and specificities of inventories included in the meta-analysis to allow readers to judge the degree to which these estimates reflected true MDD prevalence. We invite Levis and colleagues to apply these parameters to the instrument-specific prevalence estimates in Figure 3 in the article, as doing so demonstrates that MDD among residents is several-fold higher than in the general population.

The methods used by some primary studies in our meta-analysis have limitations. Future studies should incorporate well-validated assessment tools, longitudinal follow-up, and large sample sizes. This discussion, however, should not distract from the conclusion that resident depression and depressive symptoms are alarmingly high. The relevant question is not whether they are high but rather why they are high. The response to this question will have an important effect on residents and their patients.

Douglas A. Mata, MD, MPH

Marco A. Ramos, MPhil, MSc

Srijan Sen, MD, PhD

Author Affiliations: Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Mata); Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut (Ramos); Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor (Sen).

Corresponding Author: Douglas A. Mata, MD, MPH, Anatomic and Clinical Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115 (dmata@bwh.harvard.edu).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

1. Myers M. On the importance of anonymity in surveying medical student depression. *Acad Psychiatry*. 2003;27(1):19-20.
2. Simon GE, Rutter CM, Peterson D, et al. Does response on the PHQ-9 Depression Questionnaire predict subsequent suicide attempt or suicide death? *Psychiatr Serv*. 2013;64(12):1195-1202.
3. Trivedi MH, Wisniewski SR, Morris DW, et al. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. *J Clin Psychiatry*. 2011;72(6):757-764.
4. Fahrenkopf AM, Sectish TC, Barger LK, et al. Rates of medication errors among depressed and burnt out residents: prospective cohort study. *BMJ*. 2008;336(7642):488-491.
5. Depression management tool kit. The John D. and Catherine T. MacArthur Foundation Initiative on Depression and Primary Care. <http://otgateway.com/articles/13macarthurtoolkit.pdf>. Accessed February 2, 2016.

Treatment for Patients With Newly Diagnosed Glioblastoma

To the Editor Dr Stupp and colleagues¹ reported on the combined use of temozolomide and tumor-treating fields (TTFields) compared with temozolomide alone as adjuvant

therapy in patients with newly diagnosed glioblastoma. The study of 315 patients demonstrated improvement in progression-free survival (3.1 months) and overall survival (4.9 months) in the TTFields-treated cohort (210 patients). The question is whether this study, an interim analysis of the total study population of 695 patients, is sufficiently compelling to change current therapies for glioblastoma.

Barriers to use are manifold and include difficulty in use of the device, cost of the device, the failure of TTFields for recurrent glioblastoma, the potential palliative care effect afforded by use of TTFields, and the uncertain exact mechanism of action (as summarized in the accompanying Editorial²). As the device is currently configured, patients are required to shave their head twice per week, apply an adhesive electrode array covering nearly the entire scalp, and wear a 2.7-kg battery pack continuously for optimal benefit.

The conspicuity of the TTFields device makes any patient wearing it a subject of interest and curiosity. The cost of the device is approximately \$20 000/mo. Because the TTFields treatment requires an external portable device, it is often not covered by insurers, potentially creating a significant financial burden on the patient's family. A previous trial of patients with recurrent glioblastoma designed to show superiority of TTFields compared with physician-determined best therapy was negative.³

Whether involvement by the TTFields team (eg, assisting in device set-up, familiarizing the family and patient with operation of the device, providing replacement equipment, and 24/7 telephone access) contributes to survival benefit by way of surrogate palliative care is unclear and a potential confounder.⁴ Perhaps the greatest challenge to implementation of TTFields is acceptance by the neuro-oncology community (the clinicians primarily providing care for patients with glioblastoma).

Marc C. Chamberlain, MD

Author Affiliation: University of Washington, Seattle.

Corresponding Author: Marc C. Chamberlain, MD, University of Washington, Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Seattle, WA 98109 (chambemc@uw.edu).

Conflict of Interest Disclosures: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and reported receiving grants from Mundipharma and Amgen.

1. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. *JAMA*. 2015;314(23):2535-2543.
2. Sampson JH. Alternating electric fields for the treatment of glioblastoma. *JAMA*. 2015;314(23):2511-2513.
3. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A vs physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. *Eur J Cancer*. 2012;48(14):2192-2202.
4. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. 2010;363(8):733-742.

In Reply Tumor-treating fields are a novel approach to the treatment of cancer. In vitro and animal studies have demonstrated that the use of alternating electrical fields, at a

frequency specifically tuned to penetrate tumor cells, interferes with microtubule formation, proper localization of the cytokinetic contractile ring, and chromosomal segregation, leading to cell cycle arrest, apoptosis, and reduced clonogenic potential.¹⁻³ Little progress has been made in the treatment of glioblastoma over the last decade, yet our study demonstrated a significant improvement in both progression-free and overall survival in patients with glioblastoma.

Dr Chamberlain suggests the results we found with TTFields may be a placebo effect due to better palliative care. Medical follow-up was identical in both treatment groups. Although the patients treated with TTFields had access to a 24-hour hotline, it was intended for possible technical problems with the device. Once the first 2 to 3 weeks of treatment had passed, most patients became independent with the device, and intervention by the technician was limited to 1 visit per month to supply new materials, record the use of the device, and solve any technical problems.

The placebo effect is also thought to be an unlikely explanation based on the results of 2 large randomized trials comparing intensified maintenance therapy with either dose-dense temozolomide (21 d/mo vs 5 d/mo)⁴ or the addition of cilengitide (requiring twice weekly visits to the chemotherapy suite for intravenous administration).⁵ Improved outcomes were not observed in either trial with the more intensive treatment (hazard ratios for survival, 1.03 [$P = .63$] and 1.02 [$P = .86$], respectively).

Chamberlain points out that the device did not show superiority for recurrent disease⁶ (which also applies for most other treatments used), thus contradicting the placebo hypothesis. In the recurrent setting, TTFields was used as a single modality in very advanced disease, rather than in combination with chemotherapy in newly diagnosed patients.

We consider the difficulty in using the device to be quite limited (the second-generation device weighs 1.3 kg), and the electrodes are hidden easily beneath a cap or a wig. It is up to the patient to decide whether the improvement in the 2-year survival rate by 50% (from 29% to 43%) is worth it. The cost of cancer treatments is a growing concern in all of oncology. The costs, albeit substantial, are in the range of many other cancer therapies.

Chamberlain speculated about resistance by the neurooncology community to accept the results of the trial. It is difficult to explain why open and critical scientific minds would refuse to integrate sound clinical trial results into practice, even if the results were unexpected, especially when better alternatives are in short supply. Although the results were interim, they were scrutinized for a best and worst case scenario, and it is unlikely that the final results will show a substantially different outcome.

Roger Stupp, MD
Steven A. Toms, MD
Santosh Kesari, MD, PhD

Author Affiliations: Department of Oncology, University Hospital Zurich, Zurich, Switzerland (Stupp); Department of Neurosurgery, Geisinger Health

System, Danville, Pennsylvania (Toms); Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute, Santa Monica, California (Kesari).

Corresponding Author: Roger Stupp, MD, Department of Oncology, University Hospital Zurich, Raemi-St 100, Zurich 8091, Switzerland (roger.stupp@usz.ch).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Stupp reported receiving research and travel grants from Novocure and serving on advisory boards for Roche/Genentech, Merck KGaA Darmstadt, MSD/Merck, and Novartis. Dr Toms reported serving on the strategic advisory boards for Novocure and Medtronic. Dr Kesari reported receiving a grant from Novocure.

1. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. *Cancer Res*. 2004;64(9):3288-3295.
2. Kirson ED, Dabaly V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. *Proc Natl Acad Sci U S A*. 2007;104(24):10152-10157.
3. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. *Sci Rep*. 2015;5:18046.
4. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. *J Clin Oncol*. 2013;31(32):4085-4091.
5. Stupp R, Hegi ME, Gorlia T, et al; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2014;15(10):1100-1108.
6. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A vs physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. *Eur J Cancer*. 2012;48(14):2192-2202.

China's One-Child Policy

To the Editor Dr Hesketh and colleagues¹ provided a summary and critique of China's one-child policy, expressing skepticism that eliminating this policy will cause fertility rates in China to rebound. The authors delineated several positive aspects of the one-child policy. However, those apparent positives are mitigated by the corresponding costs associated with them.

The first positive aspect was the reduction of the total fertility rate, its resulting prevention of 400 million births, and the corresponding short-run demographic dividend. However, this is unlikely to create a demographic dividend in the long run.²

The second positive aspect, the reduction of female morbidity and mortality risk from fewer pregnancies, overlooked the morbidity and mortality risks associated with the lack of family support and higher incidence of loneliness in the elderly that having only 1 child could exacerbate.

The third positive aspect was the acceleration toward gender equality. How can a policy that resulted in the sex-selective abortion of millions of girls simply because they were identified as female, and that caused a gender imbalance and a corresponding market for trafficking young women, be viewed as accelerating a movement toward gender equality? As China implements its two-child policy, it remains to be seen whether the country will experience a more rapid convergence toward gender balance and whether other forms of child gender bias (unable to be manifested within 1-child families) will replicate the bias that continued to exist in the multichild households permitted by China.